Celltrion To Jostle For Space In Crowded EU Bevacizumab Market
As Celltrion Also Submits Phase III Interchangeable Humira Data
The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the critical late-stage cancer treatment.
